Litcius/Paper detail

De Novo Design of Efficient NIR‐II‐Activated Heavy‐Atom‐Free Type‐I Photosensitizer for Anti‐Tumor Photoimmunotherapy

Huan Chen, Yu Wang, Yu Wang, Zhangxin He, Yingpeng Wan, Chen Cao, Ziwei Lu, Yijian Gao, Xiao Cui, Ka‐Wai Lee, Jihua Tan, Wenchang Xu, Yuliang Yang, Xiliang Li, Yali Wang, Yali Wang, Jianquan Hou, Shengliang Li, Chun‐Sing Lee

2025Advanced Materials24 citationsDOIOpen Access PDF

Abstract

Abstract Type‐I photosensitizers (PSs) are considered to be efficient agents for overcoming the oxygen‐dependent deficiency of traditional photodynamic therapy (PDT). However, it is still challenging to design type‐I PSs that can be activated by the second near‐infrared (NIR‐II) irradiation. Herein, a series of organic heavy‐atom‐free molecules are designed (named as CTU1 , CTU2 , and CTU3 ) and exhibit strong absorption bands over the first near‐infrared and NIR‐II regions. Among them, water‐dispersible CTU3 nanoparticles (NPs) show strong J ‐aggregate characteristics and a good NIR‐II absorption band, resulting in highly efficient •O 2 − generation upon irradiation of 1064 nm light. In addition, the CTU3 NPs also exhibit a high photothermal conversion efficiency of 88.6%. In vitro and in vivo experiments show that CTU3 NPs have superior PDT and photothermal therapy (PTT) effects, which can further induce immunogenic cell death and activate immune cells in 4T1 tumor‐bearing mice for combined PDT/PTT anti‐tumor photoimmunotherapy against refractory tumors. This work presents a paradigm of de novo design of NIR‐II light‐activated type‐I PS for combinational photoimmunotherapy of cancer.

Topics & Concepts

Photothermal therapyPhotosensitizerPhotodynamic therapyMaterials scienceIrradiationAbsorption (acoustics)In vivoNanoparticleCancer researchNanotechnologyPhotochemistryChemistryMedicineBiologyBiotechnologyNuclear physicsPhysicsOrganic chemistryComposite materialNanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesAdvanced Nanomaterials in Catalysis
De Novo Design of Efficient NIR‐II‐Activated Heavy‐Atom‐Free Type‐I Photosensitizer for Anti‐Tumor Photoimmunotherapy | Litcius